MAI Capital Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

MAI Capital Management’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-951	Closed	-$98.8K	–	4025
2026 Q1	$98.8K	Hold	951	–	–	﹤0.01%	1838
2025 Q4	$98.1K	Buy	951 +7	+0.7%	+$681	﹤0.01%	1649
2025 Q3	$85.3K	Buy	944 +6	+0.6%	+$526	﹤0.01%	1649
2025 Q2	$82.5K	Sell	938 -61	-6%	-$5.29K	﹤0.01%	1579
2025 Q1	$91K	Sell	999 -57	-5%	-$5.13K	﹤0.01%	1442
2024 Q4	$91.1K	Buy	+1,056	New	+$95.5K	﹤0.01%	1486

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

MAI Capital Management's PPH Position: Q2 2026 in Review

MAI Capital Management sold out of VanEck Pharmaceutical ETF (PPH) in Q2 2026, closing a stake of 951 shares — an estimated $98.8K sold.

MAI Capital Management first reported a position in PPH in Q4 2024 and held it in 6 quarters. The position peaked at $98.8K in Q1 2026. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

MAI Capital Management reported no remaining VanEck Pharmaceutical ETF position as of Q2 2026 after selling out during the quarter.
MAI Capital Management sold 951 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $98.8K.
MAI Capital Management first reported a position in VanEck Pharmaceutical ETF in Q4 2024 and held it in 6 quarters.
MAI Capital Management's VanEck Pharmaceutical ETF position peaked at $98.8K in Q1 2026.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.